Skip to content

CRP-guided Transanal Drainage Removal After Rectal Surgery

A Single Arm Study to Investigate the Safety and Efficacy of C Reactive Protein (CRP) Guided Transanal Drainage Tube (TDT) Removal for Anastomotic Leak (AL) Prevention Following Laparoscopic Anterior Resection for Rectal Carcinoma

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05502354
Enrollment
250
Registered
2022-08-16
Start date
2023-04-01
Completion date
2025-02-01
Last updated
2023-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anastomotic Leak, Rectal Cancer

Brief summary

Transanal drainage tube (TDT) has the benefit of reducing intraluminal pressure after rectal surgery and may provide ideal regional environment for anastomotic healing. Postoperative C-reactive protein (CRP) trajectory has a high negative predictive value of 0.99 for ruling out anastomotic leak (AL). Previously, TDT was removed at the surgeon's own discretion. In the present study, we design a single arm study to investigate the safety and efficacy of CRP-guided TDT removal for AL prevention following laparoscopic anterior resection for rectal carcinoma

Interventions

DEVICEremoval of transanal drainage tube

removal of transanal drainage tube after laparoscopic anterior resection for rectal carcinoma according to postoperative CRP trajectory

Sponsors

Qilu Hospital of Shandong University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* age from 18 to 75 years old * male and female * primary rectal adenocarcinoma * ASA I, II, or III * laparoscopic LAR + DST * with or without preoperative radio- or chemotherapy * no distal metastasis * no preoperative bowel obstruction * no preventive ileostomy or colostomy * patients and their families can understand and are willing to participate in this study and provide written informed consent

Exclusion criteria

* emergency operation * preoperative abnormal liver function * tatme or ISR procedure (healing process might differ from anterior resection) * severe postoperative (Clavien-Dindo grade III IV V) complications other than anastomotic leak * severe perioperative infection unrelated to anastomotic leak * patients with serious mental illness * pregnant or breastfeeding women * patients with other clinical and laboratory conditions considered by the investigator should not participate in the trial

Design outcomes

Primary

MeasureTime frameDescription
anastomotic rate30 days after surgeryanastomotic rate

Secondary

MeasureTime frameDescription
the grades of anastomotic leak30 days after surgeryThe severity grading of anastomotic leak according to the International Study Group of Rectal Cancer
rates of diarrhea after transanal drainage tube removalfrom transanal drainage tube removal to 30 days after surgeryrates of diarrhea after transanal drainage tube removal
visual analogue scale to assess anal postoperative painfrom the date of transanal drainage tube positioning until the tube is removed, assessed up to 2 weeksvisual analogue scale of the included patients to assess the transanal drainage tube tolerability. Visual analogue scale ranges from 0-10. 0 indicates perfectly tolerated while 10 indicates complete intolerant and the tube has to be removed.
transanal drainage tube-related adverse eventsfrom the date of transanal drainage tube positioning until the tube is removed, assessed up to 2 weekstransanal drainage tube-related adverse events such as bleeding and iatrogenic colonic perforations

Countries

China

Contacts

Primary ContactXiang Zhang, M.D. Ph.D.
xiang.zhang02@hotmail.com+8618560089182
Backup ContactZhiqiang Cheng, M.D. Ph.D.
hill988276@sina.com+8618560085238

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026